News & Resources

Overview

Webcast ImageWebcast
BIO Investor Forum (Replay)
10/17/17 at 9:15 a.m. PT
BIO Investor Forum
Tuesday, October 17, 2017 9:15 a.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen’s first medicine, Contrave® (naltrexone HCl and bupropion HCl extended release), was approved in the United States in September 2014 and has become the most prescribed branded obesity medication since June 2015. In Europe the drug has been approved under the brand name Mysimba™ (naltrexone HCl/ bupropion HCl prolonged relMore >>

Stock Quote

OREX (Common Stock)
ExchangeNASDAQ (US Dollar)
Financial Status IndicatorD
Price$1.87
Change (%) Stock is Down 0.02 (1.06%)
Volume206,637
Oct 18, 2017 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More >>
DateTitle 
10/13/17Orexigen Announces Favorable Decision from U.S. District Court in Patent Litigation, Confirming Exclusivity for Contrave Through 2030Printer Friendly Version
10/12/17Orexigen Therapeutics to Provide Business Update at the 2017 BIO Investor ForumPrinter Friendly Version
09/26/17Orexigen Therapeutics Launches Next Stage of a Dynamic Campaign to Educate Consumers About Contrave®Printer Friendly Version
09/13/17Orexigen Therapeutics to Provide Business Update at the 2017 Cantor Fitzgerald Global Healthcare ConferencePrinter Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.